Related Experiment Video
Updated: May 9, 2026
06:41
Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining
Published on: July 19, 2024
Benznidazole modulates cell proliferation in acute leukemia cells
Karina Lucrecia Calvo1, María Teresa Ronco, Nélida Inés Noguera
1Instituto de Inmunología, Facultad Ciencias Médicas, Universidad Nacional Rosario, Rosario, Argentina.
Immunopharmacology and Immunotoxicology
|July 17, 2013
Summary
Benznidazole (BZL) effectively inhibits leukemic cell growth without causing cell death. It controls cell cycle progression at the G0/G1 phase by increasing p27 expression.
Area of Science:
- Pharmacology
- Cell Biology
- Cancer Research
Background:
- Benznidazole (BZL), known for trypanocidal activity, exhibits anti-proliferative effects on various cell lines.
- The anti-proliferative impact of BZL on non-adherent hematopoietic cells remains uncharacterized compared to adherent cancer cell lines.
Purpose of the Study:
- To investigate the efficacy of benznidazole (BZL) on the proliferation of the leukemic cell lines THP-1 and OCI/AML3.
- To elucidate the mechanism underlying BZL's effect on leukemic cell growth.
Main Methods:
- Cell proliferation was assessed using [³H]-thymidine incorporation and MTT assays.
- Cell death was evaluated by lactate dehydrogenase (LDH) activity.
- Apoptosis, cell cycle distribution, and protein expression were analyzed via flow cytometry and Western blotting.
Main Results:
- BZL significantly reduced proliferation in both THP-1 and OCI/AML3 cells without inducing significant cell death or apoptosis.
- Flow cytometry revealed BZL treatment led to an accumulation of cells in the G0/G1 phase and a decrease in the S phase.
- Western blot analysis showed an upregulation of the CDK inhibitor p27 and cyclin D1 in BZL-treated cells.
Conclusions:
- Benznidazole inhibits leukemic cell proliferation by arresting the cell cycle at the G0/G1 phase.
- The observed effect is mediated through the up-regulation of the p27 protein.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...